[HTML][HTML] A unique Toxoplasma gondii haplotype accompanied the global expansion of cats

L Galal, F Ariey, MA Gouilh, ML Dardé… - Nature …, 2022 - nature.com
Toxoplasma gondii is a cyst-forming apicomplexan parasite of virtually all warm-blooded
species, with all true cats (Felidae) as definitive hosts. It is the etiologic agent of …

[HTML][HTML] Is the incidence of congenital toxoplasmosis declining?

GC Milne, JP Webster, M Walker - Trends in parasitology, 2023 - cell.com
Prenatal infection with the protozoan parasite Toxoplasma gondii can cause congenital
toxoplasmosis (CT), an often fatal or lifelong-disabling condition. Several studies of human …

Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis, and management

D Devakumar, A Bamford, MU Ferreira… - The Lancet infectious …, 2018 - thelancet.com
Microcephaly is an important sign of neurological malformation and a predictor of future
disability. The 2015–16 outbreak of Zika virus and congenital Zika infection brought the …

Animals are key to human toxoplasmosis

D Schlüter, W Däubener, G Schares, U Groß… - International Journal of …, 2014 - Elsevier
Toxoplasma gondii is an extremely sucessfull protozoal parasite which infects almost all
mamalian species including humans. Approximately 30% of the human population …

Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis

K El Bissati, P Levigne, J Lykins… - Emerging microbes & …, 2018 - Taylor & Francis
Globally, congenital toxoplasmosis remains a significant cause of morbidity and mortality,
and outbreaks of infection with T. gondii represent a significant, emerging public health …

Laboratory diagnosis of congenital toxoplasmosis

C Pomares, JG Montoya - Journal of clinical microbiology, 2016 - Am Soc Microbiol
Recent studies have demonstrated that screening and treatment for toxoplasmosis during
gestation result in a decrease of vertical transmission and clinical sequelae. Early treatment …

[HTML][HTML] A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006–2016)

M Montazeri, M Sharif, S Sarvi, S Mehrzadi… - Frontiers in …, 2017 - frontiersin.org
The currently available anti-Toxoplasma agents have serious limitations. This systematic
review was performed to evaluate drugs and new compounds used for the treatment of …

[HTML][HTML] Toxoplasmosis in transplant recipients, Europe, 2010–2014

F Robert-Gangneux, V Meroni, D Dupont… - Emerging infectious …, 2018 - ncbi.nlm.nih.gov
Transplantation activity is increasing, leading to a growing number of patients at risk for
toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes …

[HTML][HTML] Functional and computational genomics reveal unprecedented flexibility in stage-specific Toxoplasma metabolism

A Krishnan, J Kloehn, M Lunghi, A Chiappino-Pepe… - Cell host & …, 2020 - cell.com
To survive and proliferate in diverse host environments with varying nutrient availability, the
obligate intracellular parasite Toxoplasma gondii reprograms its metabolism. We have …

The Toxoplasma parasitophorous vacuole: an evolving host–parasite frontier

B Clough, EM Frickel - Trends in parasitology, 2017 - cell.com
The parasitophorous vacuole is a unique replicative niche for apicomplexan parasites,
including Toxoplasma gondii. Derived from host plasma membrane, the vacuole is rendered …